Xeljanz
Found 5 free book(s)
Refusal of the marketing authorisation for Xeljanz
www.ema.europa.eu25 April 2013 . EMA/248755/2013 . EMEA/H/C/002542 . Questions and answers Refusal of the marketing authorisation for Xeljanz (tofacitinib) On 25 April 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eu6 Viral reactivation Viral reactivation and cases of herpes virus reactivation (e.g., herpes zoster) were observed in clinical studies with XELJANZ.
Rituxan® (rituximab) Medication Precertification …
www.aetna.comRituxan ® (rituximab) Medication Precertification Request . Page 3 of 3 (All fields must be completed and return both pages for precertification review)
Pfizer Pipeline
www.pfizer.comPfizer Pipeline Snapshot 4 Pipeline represents progress of R&D programs as of January 31, 2017 Included are 62 NMEs, 26 additional indications, plus 8 biosimilars
RxFiles – Drug Comparison Charts 11th Edition …
www.rxfiles.caRxFiles – Drug Comparison Charts 11th Edition (March 2017) CHART PEARLS 11th Edition Highlights of Just a Few of the Revisions Guidelines Reviewed & …